Heart failure stays a significant well being burden around the globe. Despite nice progress in delineation of molecular mechanisms underlying growth of illness, normal remedy has not superior on the similar tempo.
The multifunctional signaling molecule Ca2+/calmodulin-dependent protein kinase II (CaMKII) has acquired appreciable consideration over current years for its central function in maladaptive reworking and arrhythmias in the setting of power illness.
However, these primary science discoveries have but to translate into new therapies for human sufferers. This overview addresses each the promise and boundaries to growing translational therapies that focus on CaMKII signaling to abrogate pathologic reworking in the setting of power illness.
Efforts in small molecule design are mentioned, in addition to various focusing on approaches that exploit novel avenues for compound supply and/or genetic approaches to have an effect on cardiac CaMKII signaling. These various methods present hope for overcoming some of the challenges which have restricted the event of new therapies.
Carboxy-DCFDA N-succinimidyl ester |
|||
| GW9790-250 | Glentham Life Sciences | 250 | EUR 1427.9 |
Carboxy-DCFDA N-succinimidyl ester |
|||
| GW9790-50 | Glentham Life Sciences | 50 | EUR 379.2 |
Rabbit Anti Human IGHG4 Monoclonal Clone DCF-9 |
|||
| IRBAHUIGHG4DCF9C100UL | Innovative research | each | EUR 496 |
|
Description: Rabbit Anti Human IGHG4 Monoclonal Clone DCF-9 |
|||
Desmin (Muscle Cell Marker)(D33), CF647 conjugate, 0.1mg/mL |
|||
| BNC471722-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF647 conjugate, 0.1mg/mL |
|||
| BNC471722-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF568 conjugate, 0.1mg/mL |
|||
| BNC681722-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF568 conjugate, 0.1mg/mL |
|||
| BNC681722-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF594 conjugate, 0.1mg/mL |
|||
| BNC941722-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF594 conjugate, 0.1mg/mL |
|||
| BNC941722-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF647 conjugate, 0.1mg/mL |
|||
| BNC473069-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF647 conjugate, 0.1mg/mL |
|||
| BNC473069-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF405M conjugate, 0.1mg/mL |
|||
| BNC051722-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF405M conjugate, 0.1mg/mL |
|||
| BNC051722-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF640R conjugate, 0.1mg/mL |
|||
| BNC401722-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF640R conjugate, 0.1mg/mL |
|||
| BNC401722-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF568 conjugate, 0.1mg/mL |
|||
| BNC683069-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF568 conjugate, 0.1mg/mL |
|||
| BNC683069-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF488A conjugate, 0.1mg/mL |
|||
| BNC881722-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF488A conjugate, 0.1mg/mL |
|||
| BNC881722-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF405S conjugate, 0.1mg/mL |
|||
| BNC041722-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Desmin (Muscle Cell Marker)(D33), CF405S conjugate, 0.1mg/mL |
|||
| BNC041722-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF594 conjugate, 0.1mg/mL |
|||
| BNC943069-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF594 conjugate, 0.1mg/mL |
|||
| BNC943069-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF405S conjugate, 0.1mg/mL |
|||
| BNC043069-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF405S conjugate, 0.1mg/mL |
|||
| BNC043069-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF640R conjugate, 0.1mg/mL |
|||
| BNC403069-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF640R conjugate, 0.1mg/mL |
|||
| BNC403069-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF488A conjugate, 0.1mg/mL |
|||
| BNC883069-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Myofibroblast Marker(PR 2D3), CF488A conjugate, 0.1mg/mL |
|||
| BNC883069-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF647 conjugate, 0.1mg/mL |
|||
| BNC472843-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF647 conjugate, 0.1mg/mL |
|||
| BNC472843-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF647 conjugate, 0.1mg/mL |
|||
| BNC473075-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF647 conjugate, 0.1mg/mL |
|||
| BNC473075-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF568 conjugate, 0.1mg/mL |
|||
| BNC682843-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF568 conjugate, 0.1mg/mL |
|||
| BNC682843-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF568 conjugate, 0.1mg/mL |
|||
| BNC683075-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF568 conjugate, 0.1mg/mL |
|||
| BNC683075-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF594 conjugate, 0.1mg/mL |
|||
| BNC942843-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF594 conjugate, 0.1mg/mL |
|||
| BNC942843-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF594 conjugate, 0.1mg/mL |
|||
| BNC943075-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF594 conjugate, 0.1mg/mL |
|||
| BNC943075-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF405S conjugate, 0.1mg/mL |
|||
| BNC043075-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF405S conjugate, 0.1mg/mL |
|||
| BNC043075-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF640R conjugate, 0.1mg/mL |
|||
| BNC402843-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF640R conjugate, 0.1mg/mL |
|||
| BNC402843-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF640R conjugate, 0.1mg/mL |
|||
| BNC403075-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF640R conjugate, 0.1mg/mL |
|||
| BNC403075-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF488A conjugate, 0.1mg/mL |
|||
| BNC882843-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF488A conjugate, 0.1mg/mL |
|||
| BNC882843-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF488A conjugate, 0.1mg/mL |
|||
| BNC883075-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF488A conjugate, 0.1mg/mL |
|||
| BNC883075-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF405S conjugate, 0.1mg/mL |
|||
| BNC042843-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF405S conjugate, 0.1mg/mL |
|||
| BNC042843-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF647 conjugate, 0.1mg/mL |
|||
| BNC470612-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF647 conjugate, 0.1mg/mL |
|||
| BNC470612-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF568 conjugate, 0.1mg/mL |
|||
| BNC680612-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF568 conjugate, 0.1mg/mL |
|||
| BNC680612-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF594 conjugate, 0.1mg/mL |
|||
| BNC940612-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF594 conjugate, 0.1mg/mL |
|||
| BNC940612-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF640R conjugate, 0.1mg/mL |
|||
| BNC400612-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF640R conjugate, 0.1mg/mL |
|||
| BNC400612-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF488A conjugate, 0.1mg/mL |
|||
| BNC880612-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF488A conjugate, 0.1mg/mL |
|||
| BNC880612-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF405S conjugate, 0.1mg/mL |
|||
| BNC040612-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF405S conjugate, 0.1mg/mL |
|||
| BNC040612-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
DCFH-DA [2',7'-Dichlorodihydrofluorescein diacetate] *CAS 4091-99-0* |
|||
| 15204 | AAT Bioquest | 25 mg | EUR 86 |
DCFH-DA [2',7'-Dichlorodihydrofluorescein diacetate] *CAS 4091-99-0* |
|||
| 15204-25mg | AAT Bioquest | 25 mg | EUR 86 |
|
Description: DCFH-DA, 2',7'-Dichlorodihydrofluorescein diacetate (also called 2',7'-dichlorofluorescin diacetate), is hydrolyzed by cellular esterases to 2',7'-dichlorodihydrofluorescein (also called 2',7'-dichlorofluorescin) and is then oxidized to 2',7'-dichlorofluorescein primarily by H2O2. |
|||